GlassScriptPhysician profile
Rita Araceli Norelli
NPI 1679227821
$3,666.83
in general payments reported to CMS, 2019-2025
24 companies · $998 in 2025
The $998 reported for 2025 was more than what 94% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,215 · 2024: $1,454 · 2025: $998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,666.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $942.68 | 2023-2025 | |
| Pfizer INC. | $675.75 | 2023-2025 | |
| Glaxosmithkline, LLC. | $364.28 | 2023-2025 | Arexvy, Shingrix, Bexsero |
| Amgen INC. | $304.25 | 2023-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $263.53 | 2023-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $229.10 | 2023-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $185.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $126.77 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.78 | 2023-2025 | Xifaxan |
| Novo Nordisk INC | $88.98 | 2024-2025 | Wegovy |
| Sumitomo Pharma America, INC. | $66.95 | 2024-2025 | Gemtesa |
| Seqirus USA INC | $49.53 | 2024 | Fluad, Flucelvax |
| Kowa Pharmaceuticals America, INC. | $47.63 | 2023 | Livalo, Seglentis |
| Novartis Pharmaceuticals Corporation | $45.12 | 2023-2024 | |
| Inspire Medical Systems, INC. | $25.76 | 2024 | Inspire |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.83 | 2024 | Caplyta |
| Solventum Corporation | $20.93 | 2025 | Tegaderm, Curos, 3m Tegaderm |
| Horizon Therapeutics Plc | $18.91 | 2023 | Krystexxa |
| Exeltis, USA INC. | $16.57 | 2025 | Slynd |
| Sanofi Pasteur INC. | $16.37 | 2024 | |
| Bausch Health US, LLC | $16.07 | 2025 | Aplenzin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.73 | 2024 | |
| Merck Sharp & Dohme LLC | $13.52 | 2024 | Varivax, M-M-R II, Gardasil 9 |
| Organon LLC | $11.84 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Norelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.